Jump to any asset
849 assets, updated daily
UnitedHealth Group vs The Cigna Group
VS
Comparative Analysis
UnitedHealth Group (UNH) emerges as the stronger investment compared to Cigna Group (CI), primarily driven by its superior profitability and more consistent earnings performance. UNH demonstrates higher net profit margins and a stronger return on equity, indicating better operational efficiency and shareholder value creation. While both companies operate in the healthcare sector and face similar market dynamics, UNH's established market position and consistent execution give it an edge. CI shows potential in revenue growth, but its profitability metrics and recent earnings surprises lag behind UNH. Therefore, UNH is the preferred choice for investors seeking a more stable and profitable healthcare provider.
Key Differentiator
The most significant differentiator between UNH and CI is UNH's demonstrably superior profitability and consistent earnings performance. UNH consistently delivers higher net profit margins and has a stronger track record of beating earnings estimates, providing a more stable and predictable financial profile. While CI shows higher revenue growth, its recent earnings miss and lower profit margins suggest underlying operational inefficiencies that UNH has managed to overcome. This consistent profitability makes UNH a more reliable investment, especially in uncertain market conditions.
Joint Outlook
The outlook for UNH remains positive, supported by its consistent earnings, strong market position, and favorable analyst sentiment. While facing regulatory headwinds and medical cost pressures, its diversified business model and operational efficiency should allow it to navigate these challenges effectively. The stock's current technical weakness presents a potential entry point for long-term investors. For CI, the outlook is more mixed. The recent earnings miss raises concerns about its operational execution and profitability. However, its higher revenue growth and attractive valuation could lead to a rebound if management can demonstrate a clear path to improved earnings and margin expansion. Investors should watch for signs of stabilization in CI's earnings and a reduction in its operational risks.
Price Analysis Comparison
Valuation Metrics
| Metric | UNH | CI |
|---|---|---|
| P/E Ratio | 24.10 | 11.25 |
| Market Cap | 338.03B | 71.88B |
| Price/Sales | 0.75 | 0.25 |
| Price/Book | 3.45 | 1.68 |
| EV/EBITDA | 14.47 | 7.59 |
| Dividend Yield | 2.41% | 2.27% |
UNH trades at a P/E ratio of 24.10, which is significantly higher than CI's P/E of 11.25. This suggests that investors are willing to pay a premium for UNH's earnings, likely due to its perceived stability and growth prospects. However, when considering the price relative to its 52-week range, UNH is trading closer to its 52-week low (price $376.59, low $255.97, high $461.62) than CI (price $272.01, low $239.51, high $315.47). UNH is approximately 35% above its 52-week low, while CI is about 30% above its 52-week low. This indicates that while UNH has a higher P/E, CI is trading at a more attractive valuation on a relative basis and is closer to its 52-week high, suggesting stronger recent price momentum.
Profitability & Efficiency
| Metric | UNH | CI |
|---|---|---|
| Rev. Growth (Qtly) | 0.40% | 6.70% |
| Profit Margin | 3.14% | 2.27% |
| Return on Equity | 14.15% | 16.76% |
| Return on Assets | 4.87% | 4.46% |
| Debt/Equity | 69.21 | 74.29 |
UnitedHealth Group (UNH) exhibits superior profitability compared to Cigna Group (CI). UNH boasts a net profit margin of 3.14% and a return on equity (ROE) of 14.15%, significantly outperforming CI's net profit margin of 2.27% and ROE of 16.76%. Although CI's ROE is higher, UNH's higher net profit margin indicates more efficient conversion of revenue into profit. UNH also demonstrates a better return on assets (ROA) at 4.87% compared to CI's 4.46%, suggesting more effective utilization of its assets to generate earnings. These metrics highlight UNH's stronger operational efficiency and financial health.
Earnings Reality Check
UNH
Last 5 Qs: UNH beat estimates 3x out of 5. Rose 3x after beats.
CI
Last 3 Qs: CI beat estimates 2x out of 3. Rose 2x after beats.
Technical Indicators
| Indicator | UNH | CI |
|---|---|---|
| RSI (14) | 30.30 | 39.95 |
| 50-Day MA | $399.38 | $280.36 |
| 200-Day MA | $355.43 | $279.91 |
UNH is currently exhibiting weaker technical momentum than CI. UNH's RSI is at 30.3, indicating oversold conditions, and its MACD is at -7.17, suggesting a bearish trend. The price is below its 20-day EMA ($383.08) and 50-day SMA ($399.38), signaling short-term weakness. CI, while also showing some signs of weakness, is in a slightly better technical position. CI's RSI is 39.95, and its MACD is -2.76, both indicating a downward trend but less severe than UNH's. CI's price is also below its 20-day EMA ($276.67) and 50-day SMA ($280.36), but it is closer to its 200-day SMA ($279.91) than UNH is to its 200-day SMA ($355.43). CI's price is trading closer to its 52-week high, suggesting better recent price action.
AI Analyst Sentiment
Technical rating: based on current price action versus moving averages and momentum. This measures short-term chart trend, not analyst opinion or company fundamentals.
UNH
Technical Score: 78/100
CI
Technical Score: 55/100
Analyst sentiment favors UNH, with a 'Strong Buy' consensus from 7 analysts and 15 'Buy' ratings, totaling 22 positive recommendations against zero 'Sell' or 'Strong Sell' ratings. The median analyst target price for UNH is $490, offering a substantial upside from its current price of $376.59. CI also garners positive analyst ratings, with 6 'Strong Buy' and 13 'Buy' ratings, totaling 19 positive recommendations. However, CI's median target price of $340 is closer to its current price of $272.01, suggesting less immediate upside potential according to analysts. The strong buy-side sentiment and higher median target for UNH indicate greater confidence from the analyst community.
Risk Stratification
| Metric | UNH | CI |
|---|---|---|
| Beta (Volatility) | 0.62 | 0.32 |
| Sharpe Ratio | -0.35 | -0.33 |
For UnitedHealth Group (UNH), key risks include increasing regulatory scrutiny within the healthcare industry, potential for higher medical costs impacting margins, and competitive pressures from other large managed care organizations. Its higher valuation also presents a risk if growth expectations are not met. For Cigna Group (CI), significant risks involve its recent earnings miss and the potential for continued operational challenges impacting profitability. Its lower revenue growth compared to industry peers could also be a concern, and the company may face difficulties in expanding its market share against larger, more established players like UNH. The reliance on a few key business segments could also pose concentration risk.
Comparative ProTips
- Consider UNH for its consistent profitability and strong analyst backing, despite its higher valuation.
- Monitor CI's ability to improve its earnings performance and manage operational costs to justify its revenue growth potential.
- Both stocks are trading below their 50-day SMAs, suggesting a cautious short-term technical outlook, but UNH's oversold RSI may signal a potential rebound opportunity.
Monte Carlo Projection (10yr)
Actionable Trade Plans
Compare entry, exit, and risk management levels for both assets
Select Your Trade Bias
Risk Tolerance
Conservative
3%
Aggressive
Portfolio Value
$
✎
Position Size: $200 - $300 per asset
UNH
Current: $376.59
ENTRY ZONES
Conservative
$357.76
Aggressive
$376.59
RISK MANAGEMENT
STOP LOSS
$347.03
MAX LOSS
-3%
Volatility-Adjusted Stop Loss
Calculated based on volatility and technical support levels.
Profit Targets (Based on Conservative)
+5%
$375.65
+10%
$393.54
+15%
$411.42
CI
Current: $272.01
ENTRY ZONES
Conservative
$258.41
Aggressive
$272.01
RISK MANAGEMENT
STOP LOSS
$250.66
MAX LOSS
-3%
Volatility-Adjusted Stop Loss
Calculated based on volatility and technical support levels.
Profit Targets (Based on Conservative)
+5%
$271.33
+10%
$284.25
+15%
$297.17
Calculate Your Trade
Disclaimer
This comparison involves assets with varying risk profiles. The content is for educational purposes only. Identifying the stronger asset is based on relative strength (RS) and technical convergence. Past correlation does not guarantee future lockstep movement. Trading involves risk of loss. Note: The AI favored UNH based on profitability metrics. This is valid for the specified timeframe only.
Frequently Asked Questions
Which is a better buy, UNH or CI?+
UNH is the preferred buy due to its superior profitability, consistent earnings beats, and stronger analyst sentiment. While CI offers higher revenue growth, UNH's operational efficiency and financial stability make it a more compelling investment.
What are the key risks for UNH vs CI?+
UNH faces risks from healthcare regulation and medical cost inflation, while CI's primary risks include its recent earnings miss, potential for continued profitability challenges, and competitive pressures in a consolidating market.
How do UNH and CI compare on valuation metrics?+
CI trades at a significantly lower P/E ratio (11.25 vs 24.10) and is closer to its 52-week high, suggesting a more attractive valuation. UNH, despite its higher P/E, is further from its 52-week low, indicating a premium valuation.
Which stock has better earnings performance?+
UNH has a much stronger and more consistent record of beating earnings estimates, with its most recent quarter showing a significant positive surprise. CI's most recent earnings report missed estimates substantially.
What is the analyst sentiment for UNH and CI?+
Analyst sentiment strongly favors UNH, with a higher proportion of 'Strong Buy' ratings and a significantly higher median target price ($490) compared to CI ($340).
What are the dividend yields for UNH and CI?+
UNH offers a dividend yield of approximately 2.41%, while CI offers a yield of about 2.27%. Both are comparable, with UNH having a slight edge.